title: Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy.
abstract: OBJECTIVE
  The purpose of this study was to assess the prognostic value of (18)F-FDG PET performed at restaging in patients with locally advanced rectal cancer who previously underwent neoadjuvant radiochemotherapy.
  
  
  METHODS
  Eighty-eight patients with histologically proven rectal cancer classified at clinical TNM stages II and III were enrolled. Six weeks after radiochemotherapy completion, all patients were restaged by sonography, CT, MRI, endoscopy, and (18)F-FDG PET. Surgery was performed in all patients within 8-9 weeks from completion of radiochemotherapy. Median follow-up after surgery was 38 months (range, 6-66 months).
  
  
  RESULTS
  The 5-year overall survival and disease-free survival were 83% and 73%, respectively. Cox multivariate analysis showed that only two parameters at restaging were independent prognostic predictors of both overall survival and disease-free survival: pathologic stage and, especially, after radiochemotherapy (18)F-FDG PET findings. The 5-year overall survival was 91% in patients with a negative PET after radiochemotherapy versus 72% in those with a positive PET (p = 0.024) after radiochemotherapy, whereas disease-free survival was 81% and 62% (p = 0.003) for those with the negative and positive PET findings, respectively. Statistical data were further enhanced when combining the pathologic stage with the (18)F-FDG PET results: 95% 5-year overall survival in the PET-negative pathologic stages 0 and I patients versus 70% in PET-positive pathologic stages II-IV patients (p = 0.001), whereas disease-free survival was 93% and 65% (p = 0.0003) for the negative and positive PETs, respectively.
  
  
  CONCLUSIONS
  In patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy, the combined evaluation of pathologic stage and after-radiochemotherapy (18)F-FDG PET at restaging identified a subgroup of patients characterized by good response to radiochemotherapy and a more favorable prognosis. In these patients, a conservative surgical approach might be considered.
authors.affiliation: Radiotherapy Department, S. Maria della Misericordia Hospital, Rovigo, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Capirci
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Franca
authors.initials: F
authors.lastname: Chierichetti
authors.forename: Giorgio
authors.initials: G
authors.lastname: Crepaldi
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mandoliti
authors.forename: Simonetta
authors.initials: S
authors.lastname: Salviato
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Boni
authors.forename: Lucia
authors.initials: L
authors.lastname: Rampin
authors.forename: Cesare
authors.initials: C
authors.lastname: Polico
authors.forename: Giuliano
authors.initials: G
authors.lastname: Mariani
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D013997:Time Factors
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18